BAO PHARMA-B's stock plummeted 64.33% during intraday trading on Thursday, marking a severe decline for the biotechnology company.

The sharp drop followed the release of the company's annual report, which disclosed that net losses attributable to shareholders widened to RMB 395 million from RMB 364 million in the prior year, despite a significant 697.99% year-over-year surge in revenue. This deterioration in profitability likely triggered investor concern and a sell-off.

The stock's performance contrasted with mixed movements in the broader biotechnology sector during the session.